Last reviewed · How we verify
Inborn error of bile acid metabolism — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Cholbam | CHOLIC ACID | Mirum | Bile Acid [EPC] | G-protein coupled bile acid receptor 1 | 2015-01-01 | |
| Cholbam | Cholbam | Mirum Pharmaceuticals, Inc. | G-protein coupled bile acid receptor 1, Bile acid receptor |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Mirum · 1 drug in Inborn error of bile acid metabolism
- Mirum Pharmaceuticals, Inc. · 1 drug in Inborn error of bile acid metabolism
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Inborn error of bile acid metabolism:
- Inborn error of bile acid metabolism treatment updates — RSS
- Inborn error of bile acid metabolism treatment updates — Atom
- Inborn error of bile acid metabolism treatment updates — JSON
Cite this brief
Drug Landscape (2026). Inborn error of bile acid metabolism — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/inborn-error-of-bile-acid-metabolism. Accessed 2026-06-10.
Related
- Inborn error of bile acid metabolism full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing